Dashboard
Manage Tickers

ISEE


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

from-ai-to-obesity-drugs---global-pharma-has-700b-for-ma-and-investments-goldman-sachs
From AI to Obesity Drugs - Global Pharma H...
07/07/2023 17:18:25

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&...

Core News & Articles
On July 6, At Special Meeting Iveric Bio I...
07/06/2023 17:07:18

- Reuters 

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
05/08/2023 17:35:23

td-cowen-downgrades-iveric-bio-to-market-perform
TD Cowen Downgrades IVERIC bio to Market P...
05/08/2023 15:25:48

TD Cowen analyst Ken Cacciatore downgrades IVERIC bio (NASDAQ:ISEE) from Outperform to Market Perform.

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
05/04/2023 15:00:45

baird-downgrades-iveric-bio-to-neutral-announces-40-price-target
Baird Downgrades IVERIC bio to Neutral, An...
05/04/2023 10:08:23

Baird analyst Colleen Kusy downgrades IVERIC bio (NASDAQ:ISEE) from Outperform to Neutral and announces $40 price target.

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
05/03/2023 15:00:39

ubs-downgrades-iveric-bio-to-neutral-raises-price-target-to-40
UBS Downgrades IVERIC bio to Neutral, Rais...
05/03/2023 08:57:36

UBS analyst Eliana Merle downgrades IVERIC bio (NASDAQ:ISEE) from Buy to Neutral and raises the price target from $34 to $40.

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
05/02/2023 15:00:40

hc-wainwright--co-downgrades-iveric-bio-to-neutral-raises-price-target-to-40
HC Wainwright & Co. Downgrades IVERIC bio ...
05/02/2023 10:13:54

HC Wainwright & Co. analyst Matthew Caufield downgrades IVERIC bio (NASDAQ:ISEE) from Buy to Neutral and raises the pric...

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
05/01/2023 15:00:42

first-republic-folds-amid-banking-crisis-elon-musk-expects-starship-to-make-orbit-on-next-launch-doj-probes-mastercard-over-anti-competitive-debit-card-practices-todays-top-stories
First Republic Folds Amid Banking Crisis, ...
05/01/2023 13:58:37

Benzinga

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
05/01/2023 13:06:41

wedbush-downgrades-iveric-bio-to-neutral-raises-price-target-to-40
Wedbush Downgrades IVERIC bio to Neutral, ...
05/01/2023 12:46:46

Wedbush analyst David Nierengarten downgrades IVERIC bio (NASDAQ:ISEE) from Outperform to Neutral and raises the price targe...

astellas-pharma-acquires-iveric-bio-for-59b-to-focus-on-blindness--regeneration
Astellas Pharma Acquires Iveric Bio For $5...
05/01/2023 12:00:47

Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per sha...

iveric-bio-ascendis-pharma-and-other-big-stocks-moving-higher-in-mondays-pre-market-session
IVERIC bio, Ascendis Pharma And Other Big ...
05/01/2023 11:32:48

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. ...

guggenheim-downgrades-iveric-bio-to-neutral
Guggenheim Downgrades IVERIC bio to Neutral
05/01/2023 11:06:56

Guggenheim analyst Eddie Hickman downgrades IVERIC bio (NASDAQ:ISEE) from Buy to Neutral.

astellas-entered-into-definitive-agreement-to-acquire-iveric-bio-for-40share-in-cash
Astellas Entered Into Definitive Agreement...
04/30/2023 23:15:25

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO:...

the-latest-analyst-ratings-for-iveric-bio
The Latest Analyst Ratings for IVERIC bio
04/25/2023 18:00:54

morgan-stanley-maintains-overweight-on-iveric-bio-raises-price-target-to-35
Morgan Stanley Maintains Overweight on IVE...
04/25/2023 12:02:11

Morgan Stanley analyst Michael Ulz maintains IVERIC bio (NASDAQ:ISEE) with a Overweight and raises the price target from $30...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)